RT Journal Article
SR Electronic
T1 Antiviral metabolite 3’-Deoxy-3’,4’-didehydro-cytidine is detectable in serum and identifies acute viral infections including COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.23.21260740
DO 10.1101/2021.07.23.21260740
A1 Ravi Mehta
A1 Elena Chekmeneva
A1 Heather Jackson
A1 Caroline Sands
A1 Ewurabena Mills
A1 Dominique Arancon
A1 Ho Kwong Li
A1 Paul Arkell
A1 Timothy M. Rawson
A1 Robert Hammond
A1 Maisarah Amran
A1 Anna Haber
A1 Graham Cooke
A1 Mahdad Noursadeghi
A1 Myrsini Kaforou
A1 Matthew Lewis
A1 Zoltan Takats
A1 Shiranee Sriskandan
YR 2021
UL http://medrxiv.org/content/early/2021/07/25/2021.07.23.21260740.abstract
AB There is a critical need for improved infectious disease diagnostics to enable rapid case identification in a viral pandemic and support targeted antimicrobial prescribing. Here we use high-resolution liquid chromatography coupled with mass spectrometry to compare the admission serum metabolome of patients attending hospital with a range of viral infections, including SARS-CoV-2, to those with bacterial infections, non-infected inflammatory conditions and healthy controls. We demonstrate for the first time that 3’-Deoxy-3’,4’-didehydro-cytidine (ddhC), a free base of the only known human antiviral small molecule ddhC-triphosphate (ddhCTP), is detectable in serum. ddhC acts as an accurate biomarker for viral infections, generating an area under the receiver operating characteristic curve of 0.954 (95% confidence interval 0.923-0.986) when comparing viral to non-viral cases. Gene expression of viperin, the enzyme responsible for ddhCTP synthesis, is highly correlated with ddhC, providing a biological mechanism for its increase during viral infection. These findings underline a key future diagnostic role of ddhC in the context of pandemic preparedness and antimicrobial stewardship.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNIHR Imperial Biomedical Research Centre; Medical Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of BioAID samples was reviewed by the South Central - Oxford C Research Ethics Committee and approved (REC references 14/SC/0008 and 19/SC/0116). Use of Microbial Products in Infection samples was reviewed by the West London Research Ethics Committee and approved (REC reference 06/Q0406/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll source data will be made publicly available through the European Bioinformatics Institute (EMBL-EBI) MetaboLights repository.